DEF: Pacira BioSciences Reports Record Revenue in 2024, Advances Pipeline

Pacira BioSciences achieved record revenue of $701 million in 2024 and made significant progress in clinical and regulatory developments.

Summary

• Pacira BioSciences, Inc. achieved record revenue of $701 million in 2024.
• The company secured NOPAIN Act reimbursement for EXPAREL and iovera and facilitated coverage of EXPAREL through a new product-specific J-code.
• The FDA granted RMAT designation to PCRX-201 for osteoarthritis.
• Pacira acquired GQ Bio Therapeutics GmbH in February 2025 to enhance its ability to address unmet patient needs.
• A goodwill impairment of $163.2 million was included in the 2024 net loss.
• The company's 5x30 strategy aims to treat over three million patients per year, achieve double-digit compounded annual growth rate, improve gross margin by five percentage points, expand the clinical pipeline with five novel programs, and establish five partnerships by 2030.
• A new share repurchase plan with a $300 million authorization was initiated in April 2025, authorized through December 31, 2026.
• As of January 1, 2025, the NOPAIN Act is in full effect, providing a reimbursement pathway for 18 million outpatient surgical procedures.
• A Phase 1 study of PCRX-201 showed pain relief and durability for at least two years in 72 patients with moderate to severe OA of the knee.
• The company launched its 5x30 strategic plan in January 2025 to accelerate its transition into an innovative biopharmaceutical and therapeutic area leader.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record revenue, strategic acquisitions, and regulatory advancements. While there is a mention of a goodwill impairment, the overall tone is optimistic and forward-looking.

Positives

• Record revenue of $701 million was achieved in 2024.
• NOPAIN Act reimbursement secured for EXPAREL and iovera.
• FDA granted RMAT designation to PCRX-201.
• Acquisition of GQ Bio Therapeutics GmbH expands pipeline.
• New $300 million share repurchase plan authorized.
• EXPAREL now has its own product-specific J-code.
• Phase 1 study of PCRX-201 shows promising results.

Negatives

• A $163.2 million goodwill impairment was included in the 2024 net loss.

Risks

• The document mentions risks and uncertainties that could cause actual results and events to differ materially in the Risk Factors section of the Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

The company is focused on growth, operational excellence, and delivering innovative, non-opioid pain therapies. The 5x30 strategy is expected to drive growth and value creation. The company is progressing on these initiatives with the acquisition of GQ Bio Therapeutics GmbH in February 2025.

Management Comments

• Frank D. Lee, Chief Executive Officer: '2024 was a year of solid progress across the organization... and we see significant momentum for further value creation.'
• Frank D. Lee, Chief Executive Officer: 'I believe our 5x30 strategy will create value for stockholders through two strategic imperatives: delivering growth in our commercial-based business and building an innovative pipeline.'
• Frank D. Lee, Chief Executive Officer: 'I am inspired by the hard work of our highly committed team and am confident in our ability to capitalize on the opportunities in front of us as we grow and transform even more patients lives through the delivery of our trusted products.'

Industry Context

The announcement highlights Pacira's commitment to non-opioid pain management solutions, aligning with the broader industry trend of seeking alternatives to opioids. The acquisition of GQ Bio and the RMAT designation for PCRX-201 position Pacira as a leader in innovative pain relief solutions.

Comparison to Industry Standards

• The document mentions several comparable companies in the pharmaceutical and biotechnology industries, including ACADIA Pharmaceuticals, Alkermes, Amicus Therapeutics, and others.
• These companies are used as a peer group for executive compensation benchmarking.
• The document positions Pacira's revenue and market capitalization relative to this peer group.
• The company's 5x30 strategy sets specific targets for patient reach, revenue growth, profitability, pipeline expansion, and partnerships, which can be compared to the strategic goals of other companies in the industry.
• The document highlights Pacira's efforts to combat the opioid epidemic, which is a significant concern across the healthcare industry.

Management Changes

Corporate Governance

Related Party Transactions

• Transition and Retirement Agreement with former CEO David Stack.
• Consulting Agreement with former CEO David Stack.

Stakeholder Impact

• Shareholders: Potential for increased value through growth and strategic initiatives.
• Patients: Expanded access to non-opioid pain therapies.
• Employees: Opportunities for growth and development within the organization.

Next Steps

• Execute on the 5x30 strategy.
• Maximize the commercial portfolio of opioid-sparing products.
• Advance the pipeline of innovative pain relief solutions.

Key Dates

Keywords

EXPAREL, ZILRETTA, iovera, PCRX-201, revenue, non-opioid, pain management, Pacira BioSciences, RMAT designation, acquisition, pipeline, reimbursement, J-code